2025.06.26 (목)

  • 구름많음속초22.7℃
  • 흐림24.1℃
  • 흐림철원22.6℃
  • 구름많음동두천22.3℃
  • 구름많음파주23.3℃
  • 구름조금대관령19.3℃
  • 흐림춘천24.0℃
  • 구름많음백령도21.7℃
  • 구름많음북강릉25.9℃
  • 구름조금강릉27.0℃
  • 구름조금동해22.6℃
  • 흐림서울23.9℃
  • 구름많음인천23.0℃
  • 흐림원주22.6℃
  • 흐림울릉도21.8℃
  • 구름많음수원24.2℃
  • 흐림영월22.0℃
  • 구름많음충주23.6℃
  • 구름많음서산22.8℃
  • 구름조금울진21.0℃
  • 흐림청주25.3℃
  • 흐림대전25.0℃
  • 구름많음추풍령24.1℃
  • 구름많음안동24.6℃
  • 흐림상주24.9℃
  • 구름많음포항23.7℃
  • 구름조금군산22.8℃
  • 구름많음대구27.1℃
  • 구름많음전주25.5℃
  • 구름많음울산26.8℃
  • 구름많음창원25.7℃
  • 구름많음광주26.2℃
  • 구름많음부산22.5℃
  • 흐림통영23.0℃
  • 구름많음목포23.9℃
  • 흐림여수23.2℃
  • 흐림흑산도20.8℃
  • 구름조금완도25.2℃
  • 구름많음고창24.8℃
  • 구름많음순천25.6℃
  • 구름많음홍성(예)23.5℃
  • 흐림24.5℃
  • 구름조금제주25.1℃
  • 구름많음고산22.9℃
  • 구름많음성산24.0℃
  • 구름조금서귀포24.3℃
  • 구름많음진주26.4℃
  • 구름많음강화21.4℃
  • 구름많음양평23.4℃
  • 구름많음이천23.9℃
  • 구름많음인제23.1℃
  • 흐림홍천22.9℃
  • 구름조금태백20.4℃
  • 흐림정선군22.6℃
  • 흐림제천22.1℃
  • 흐림보은23.3℃
  • 흐림천안23.4℃
  • 구름많음보령22.6℃
  • 구름조금부여24.9℃
  • 구름많음금산25.0℃
  • 흐림23.7℃
  • 구름많음부안23.3℃
  • 구름많음임실24.9℃
  • 구름많음정읍24.5℃
  • 구름많음남원26.0℃
  • 구름많음장수23.8℃
  • 구름많음고창군25.0℃
  • 구름많음영광군24.1℃
  • 구름조금김해시24.9℃
  • 구름조금순창군26.3℃
  • 구름많음북창원26.6℃
  • 구름많음양산시26.5℃
  • 구름많음보성군27.4℃
  • 구름많음강진군26.5℃
  • 구름많음장흥26.3℃
  • 구름많음해남25.0℃
  • 구름많음고흥25.8℃
  • 구름많음의령군27.7℃
  • 구름많음함양군27.7℃
  • 구름많음광양시27.1℃
  • 구름많음진도군23.9℃
  • 흐림봉화22.2℃
  • 구름많음영주22.7℃
  • 흐림문경23.3℃
  • 구름많음청송군24.4℃
  • 구름많음영덕23.8℃
  • 흐림의성25.8℃
  • 구름많음구미26.3℃
  • 구름많음영천25.5℃
  • 구름많음경주시27.5℃
  • 구름많음거창26.1℃
  • 구름많음합천28.6℃
  • 구름많음밀양29.6℃
  • 구름많음산청27.1℃
  • 구름많음거제23.3℃
  • 흐림남해25.8℃
  • 구름많음25.6℃
기상청 제공
Shoppy 로고
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
  • 해당된 기사를 공유합니다

Cancellation of remaining publicly held registered shares of Vifor Pharma AG

Last trading day of Vifor registered shares: 22 December 2022
Delisting date of Vifor registered shares: 23 December 2022

Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a “Vifor Share”). The Commercial Court's decision has become legally effective (rechtskräftig) and is published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt; SHAB) by the Commercial Court.

Vifor further announced today that SIX Exchange Regulation AG has determined the last trading day and the delisting date of the Vifor Shares at and from SIX Swiss Exchange as follows:

Last trading day: 22 December 2022

Delisting date: 23 December 2022

As a result of the cancellation of the remaining publicly held Vifor Shares, each holder of cancelled Vifor Shares is entitled to a compensation of USD 179.25 in cash per cancelled Vifor Share. The envisaged settlement date for payment of such compensation against delivery of the cancelled Vifor Shares is 28 December 2022.

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.

Forward-Looking Statements

This announcement may contain statements that constitute forward-looking statements. The words “anticipate”, “believe”, “expect”, “estimate”, “aim”, “project”, “forecast”, “estimate”, “risk”, “likely”, “intend”, “outlook”, “should”, “could”, “would”, “may”, “will”, “continue”, “plan”, “probability”, “indicative”, “seek”, “target”, “plan” and other similar expressions are intended to identify forward-looking statements.

Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of CSL and Vifor and their officers, employees, agents and advisors, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and may cause actual results to differ materially from those expressed or implied in such statements. You are strongly cautioned not to place undue reliance on forward-looking statements.

This announcement is not a financial product or investment advice, a recommendation to acquire or sell securities or accounting, legal or tax advice. It does not constitute an invitation or offer to apply for securities. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate for their jurisdiction. CSL and Vifor are not licensed to provide financial product advice in respect of an investment in securities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005876/en/

언론연락처: CSL Vifor Media Contact Thomas Hutter Mobile: +41 79 957 96 73 Investor Contact CSL Limited Steve McKeon Associate Director, Investor Relations Mobile +61 402 231 696 Switzerland / Europe Martin Meier-Pfister (IRF) + 41 432 448 140

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기